10-17-2024Cross-posted from: NIAID Newsroom Kidney transplantation from deceased donors with HIV (HIV D+) to recipients...
NIAID Newsroom
Kidney Transplantation Between Donors and Recipients with HIV Is Safe Exploratory Analysis Associates HIV Drug Abacavir with Elevated Cardiovascular Disease Risk in Large Global Trial 07-26-2024Cross-posted from: NIAID Newsroom Transmission electron micrograph of HIV-1 virus particles (teal) budding and...Long-Acting Injectable Cabotegravir for HIV Prevention Is Safe in Pregnancy 07-25-2024Cross-posted from: NIAID Newsroom Transmission electron micrograph of HIV-1 virus particles (green) replicatin...An Isolated Viral Load Test May Generate False Positive Results for People Using Long-Acting PrEP 07-23-2024Colorized transmission electron micrograph of multiple HIV-1 virus particles (green) budding from a cell projec...U.S. Clinical Trials Begin for Twice-Yearly HIV Prevention Injection 06-07-2024Cross-posted from NIAID Newsroom Colorized transmission electron micrograph of numerous HIV-1 virus particles...Sexually Transmitted Infections—A Closer Look at NIAID Research 04-17-2024Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites. STIs have a devastating...Statement: Long-Acting HIV Treatment Demonstrates Efficacy in People with Challenges Taking Daily Medicine as Prescribed 02-22-2024Cross-posted from: NIAID Newsroom Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine...Working Together to End HIV in Black Communities 02-07-2024Health inequities and disparities disproportionately affect Black people and other historically marginalized gro...Biomedical STI Prevention Evidence Is Inadequate for Cisgender Women 01-10-2024Note: As we continue to pursue the goals of both the STI National Strategic Plan and National HIV/AIDS Strateg...NIH Research Identifies Opportunities to Improve Future HIV Vaccine Candidates 12-20-2023Cross-posted from: NIAID Newsroom An effective HIV vaccine may need to prompt strong responses from immune...NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic Developed Through Public-Private Partnership 11-14-2023Scanning electron micrograph of Neisseria gonorrhoeae bacteria, which causes gonorrhea. Captured by the Research...The STOMP Trial Evaluates an Antiviral for Mpox 10-10-2023Cross-posted from:NIAID Newsroom Following a peak in the summer of 2022, new infections in the mpox clade IIb outbreak have decreased, due in part to the...Clinical Trial of HIV Vaccine Begins in United States and South Africa 09-26-2023Cross-posted from: NIAID newsroom Transmission electron micrograph of HIV-1 virus particles from infected H9 c...Daily Statin Reduces the Risk of Cardiovascular Disease in People Living with HIV, Large NIH Study Finds 04-14-2023Cross-posted from NIAID Newsroom A National Institutes of Health (NIH) clinical trial was stopped early because...Experimental HIV Vaccine Regimen Safe but Ineffective, NIH Study Finds 01-19-2023Cross-posted from NIAID Newsroom An investigational HIV vaccine regimen tested among men who have sex with men...Early HIV Diagnosis and Treatment Important for Better Long-term Health Outcomes 11-02-2022Cross-posted from NIAID Newsroom Antiretroviral drugs to treat HIV infection Credit: NIAID Starting antiretro...Three-dose Hepatitis B Vaccine Regimen Protects People with HIV 10-21-2022Cross-posted from NIH s NIAID Newsroom Finding is part of an ongoing clinical trial. A three-dose course of...Clinical Trial Evaluating Monkeypox Vaccine Begins 09-09-2022Cross-posted from NIAID Newsroom NIH Trial is Evaluating Intradermal Delivery to Expand the Vaccine Supply....Combination Anti-HIV Antibody Infusions Suppress Virus for Sustained Period 06-02-2022NIH Launches Clinical Trial of Three mRNA HIV Vaccines 03-23-2022